Pharmacokinetics of Bevacizumab after Topical, Subconjunctival, and Intravitreal Administration in Rabbits

Hiroyuki Nomoto, Fumio Shiraga, Noriyuki Kuno, Erika Kimura, Shinobu Fujii, Katsuhiko Shinomiya, Alex K. Nugent, Kazuyuki Hirooka, Tetsuya Baba
2009 Investigative Ophthalmology and Visual Science  
PURPOSE. To investigate the pharmacokinetics of bevacizumab in rabbits for three different routes of administrations: intravitreal injection, subconjunctival injection, and eye drops. METHODS. Pigmented rabbits received bevacizumab in one eye by topical eye drops (1.25 mg/0.05 mL six times daily for the first 7 days), single subconjunctival injection (1.25 mg/0.05 mL), or single intravitreal injection (1.25 mg/0.05 mL). Bevacizumab concentrations in plasma and ocular tissues in the treated and
more » ... ellow eyes were determined by sandwich enzymelinked immunosorbent assay at 1, 2, 4, and 12 weeks after administration. RESULTS. After intravitreal injection in the treated eye, the mean maximum concentrations (C max ) of bevacizumab in the iris/ ciliary body and retina/choroid were 109,192.6, and 93,990.0 ng/g, respectively, whereas after subconjunctival injection, the C max was 1418.7 and 295.8 ng/g, respectively. In the fellow eyes, when the drug was administered by intravitreal injection, the C max was 753.6 ng/g in the iris/ciliary body and 224.2 ng/g in the retina/choroid and by subconjunctival injection was 1192.9 and 187.0 ng/g, respectively. With eye drops, only a small level of bevacizumab was detected in the iris/ciliary body and retina/choroid. Systemic exposure to bevacizumab was at the same level when administered by intravitreal or subconjunctival injection. CONCLUSIONS. Intravitreal injection of bevacizumab was the most effective route of administration for intraocular tissue. Also, bevacizumab injected subconjunctivally was transported into the intraocular tissues of the treated eyes at an effective level. Both intravitreal and subconjunctival injections of bevacizumab resulted in high plasma concentrations. Bevacizumab was distributed into the intraocular tissues in fellow eyes via the systemic circulation. This treatment may be effective for blocking vascular endothelial growth factor activity. (Invest Ophthalmol Vis Sci. 2009;50: 4807-4813)
doi:10.1167/iovs.08-3148 pmid:19324856 fatcat:wiu4uvnc7za7xexzxrji7dmjea